



04/19/99

Customer No. 20350

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
(415) 576-0200

**ASSISTANT COMMISSIONER FOR PATENTS**  
**BOX PATENT APPLICATION**  
**Washington, D.C. 20231**

Sir:

Transmitted herewith for filing under 37 CFR 1.53(b) is the

- ☐ patent application of  
☒ continuation patent application of  
☐ divisional patent application of  
☐ continuation-in-part patent application of

Inventors: CHRISTOPHER J. ONG, JOHN J. PRIATEL, FRANK R. JIRIK

For: COMPLEMENTATION TRAP

- ☒ This application claims priority from each of the following Application Nos./filing dates:  
Canadian appl. No. 2,205,888, filed July 11, 1997 and PCT/CA98/00677, filed July 10, 1998  
 the disclosure(s) of which is (are) incorporated by reference.
- ☒ Please amend this application by adding the following before the first sentence: "This application is a ☒ continuation ☐ continuation-in-part of and claims the benefit of PCT Application No. PCT/CA98/00677, filed July 10, 1998, the disclosure of which is incorporated by reference."

Enclosed are:

- ☒ 45 page(s) of specification  
☒ 3 page(s) of claims  
☒ 1 page(s) of Abstract  
☒ 1 sheet(s) of ☐ formal ☒ informal drawing(s).
- An assignment of the invention to \_\_\_\_\_
- ☒ A ☐ signed ☒ unsigned Declaration & Power of Attorney  
☐ A ☐ signed ☐ unsigned Declaration.  
☐ A Power of Attorney.  
☐ A verified statement to establish small entity status under 37 CFR 1.9 and 37 CFR 1.27 ☐ is enclosed ☐ was filed in the prior application and small entity status is still proper and desired.  
☐ A certified copy of a \_\_\_\_\_ application.  
☐ Information Disclosure Statement under 37 CFR 1.97.  
☐ A petition to extend time to respond in the parent application.  
☐ Notification of change of ☐ power of attorney ☐ correspondence address filed in prior application.  
☒ Preliminary Amendment

**In view of the Unsigned Declaration as filed with this application and pursuant to 37 CFR §1.53(f),**  
**Applicant requests deferral of the filing fee until submission of the Missing Parts of Application.**

DO NOT CHARGE THE FILING FEE AT THIS TIME.

Telephone:  
(415) 576-0200

Facsimile:  
(415) 576-0300

Attorney Docket No. 80135-0Client Ref No. 80021-94"Express Mail" Label No. EL008719787USDate of Deposit: April 19, 1999

I hereby certify that this is being deposited with the United States  
 Postal Service "Express Mail Post Office to Addressee" service  
 under 37 CFR 1.10 on the date indicated above, addressed to:

Assistant Commissioner for Patents  
 Washington, D.C. 20231

By: \_\_\_\_\_

jc518 U.S. PTO  
09/295464  
04/19/99

Eugenia Garrett-Warkowski  
 Reg No.: 37,330  
 Attorneys for Applicant

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Continuation Application  
based on PCT/CA98/00677 of

Art Unit: Not yet assigned

CHRISTOPHER J. ONG, et al.

Application No.: Not yet assigned

Filed: Herewith

PRELIMINARY AMENDMENT

For: COMPLEMENTATION TRAP

San Francisco, CA 94111  
April 19, 1999

Box PCT  
Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Prior to examination of the above-referenced application, please enter the following amendments and remarks.

IN THE CLAIMS:

Claim 3, line 1, please delete "and 2".

Claim 4, line 1, delete "or 2".

Claim 5, line 1, delete "or 2".

Claim 6, line 1, delete "any one of claims 1-5" and substitute therefor


--claim 1--.

Claim 11, line 1, delete "or 10".

REMARKS

Amendment is made to delete all multiple dependencies from the claims,  
thereby avoiding the need to pay the multiple dependent surcharge.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Eugenia Garrett Wackowski', is written over the typed name and registration number.

Eugenia Garrett Wackowski  
Reg. No. 37,330

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: (415) 576-0200  
Fax: (415) 576-0300  
EGW/tp  
SF 212662 v1

COMPLEMENTATION TRAPField of the Invention

5

The present invention relates to gene entrapment vectors and their use in gene discovery, and their use in screening for or making cells and organisms that are mutated for such genes. This invention also relates to the use of such entrapment vectors to identify tissue specific transcription control elements such as promoters and enhancers and for generating transgenic animals displaying restricted expression of transgenes. This invention also relates to trap vectors comprising a splice acceptor and a sequence encoding a reporter gene.

10  
15Background of the Invention

Genomic based drug discovery is largely dependent upon the identification of specific genomic targets. Thus, cloning, sequencing, and identification of function of mammalian genes is a first priority in a genomic based drug discovery. In particular, it is important to identify and make use of genes which are spacially and/or temporally regulated in the organism.

20  
25

Animal model systems such as the fruit fly and the worm are often used in gene identification because of ease of manipulation of the genome and ability screen for mutants. While these systems have their limitations, large numbers of developmental mutations have been identified in those organisms either by monitoring the phenotypic effects of mutations or by screening for expression of reporter genes incorporated into developmentally regulated genes.

30  
35

Many features of the mouse make it the best animal model system to study gene function. However, the mouse has not been used for large scale classical genetic mutational analysis because random mutational screening and

- 2 -

analysis is very cumbersome and expensive due to long generation times and maintenance costs.

A disadvantage in using animal models for the identification of genes is the need to establish a transgenic animal line for each mutational event. This disadvantage is alleviated in part by using embryonic stem (ES) cell lines because mutational events may be screened in vitro prior to generating an animal. ES cells are totipotent cells isolated from the inner cell mass of the blastocyst. Methods are well known for obtaining ES cells, incorporating genetic material into ES cells, and promotion of differentiation of ES cells. ES cells may be caused to differentiate in vitro or the cells may be incorporated into a developing blastocyst in which the ES cells will contribute to all differentiated tissues of the resulting animal. Vectors for transforming ES cells and suitable genes for use as reporters and selectors are also well known.

Gene entrapment strategies have been employed to identify developmentally regulated genes. One type of entrapment vector is called a "promoter trap", which consists of a reporter gene sequence lacking a promoter. Its integration is detected when the reporter is integrated "in-frame" into an exon. "Gene trap vectors" target the much more prevalent introns of the eucaryotic genome. The latter vectors consist of a splice-acceptor site upstream from a reporter gene. Integration of the reporter into an intron results in a fusion transcript containing RNA from the endogenous gene and from the reporter gene sequence.

Gene trap vectors may be made more efficient by incorporation of an internal ribosomal entry site (IRES) such as that derived from the 5' non-translated region of encephalomyocarditis virus (EMCV). Placement of a IRES

- 3 -

site between the splice acceptor and the reporter gene of a gene trap vector means that reporter gene product need not be translated as a fusion product with the endogenous gene product, thereby increasing the likelihood that  
5 integration of the vector will result in expression of the reporter gene product.

Examples from the literature of the use of promoter and gene trap vectors as well as such vectors including an  
10 IRES sequence, are listed below. Some examples involve the identification of developmentally regulated or tissue specific events making use of ES cell lines.

1. Canadian Patent application no. 2,166,850 (open for  
15 public inspection July 11, 1996) Vectors and the Use Thereof for Capturing Target Genes: describes the use of transmembrane sequence encoding gene trap vectors to isolate and identify secretory proteins. Also see United States Patent No. 5,767,336 issued June 16, 1998.

20

2. US Patent 5,364,783 issued Nov. 15, 1994. Retrovirus Promoter Trap Vectors: describes retroviral vectors that are used to isolate transcriptionally active chromosomal  
25 regions and to identify promoter sequences. The reporter gene is placed in the U3 or U5 control region of the retrovirus.

2. Gossler, A., et al. (1989). Mouse Embryonic Stem Cells and Reporter Constructs to Detect Developmentally Regulated Genes. Science 244:463-465: describes the use of enhancer trap gene trap vectors for use in identifying developmentally regulated genes. The gene trap vector consists of the mouse En-2 splice acceptor upstream from  
35 lacZ (reporter) and a selector gene (hBa-neo).

- 4 -

3. Von Melchner, H., et al.: Isolation of Cellular Promoters by Using a Retrovirus Promoter Trap. Proc. Natl. Acad. Sci. USA 1990, 87:3733-3737.
- 5 3. MacLeod, D., et al.: A Promoter Trap in Embryonic Stem (ES Cells Selects for Integration of DNA into CpG Islands. Nucleic Acids Res. 1991, 19:17-23.
- 10 4. Reddy, S., et al.: Retrovirus Promoter-Trap Vector to Induce lacA Gene Fusions in Mammalian Cells. J. Virol. 1991, 65:1507-1515.
- 15 5. Brenner, D.G., et al.: Analysis of Mammalian Cell Genetic Regulation in Situ by Using Retrovirus-Derived Portable Exons Carrying the Escherichia coli lacZ Gene. Proc. Natl. Acad. Sci. USA. 1989, 86:5517-5521.
- 20 6. Kerr, W.G., et al.: Transcriptional Defective Retroviruses Containing lacZ for the in Situ Detection of Endogenous Genes and Developmentally Regulated Chromatin. Cold. Spring. Harb. Symp. Quant. Biol. 1989, 54:767-776.
- 25 7. Friedrich, G. and Soriano, P.: Promoter Traps in Embryonic Stem Cells: A Genetic Screen to Identify and Mutate Developmental Genes in Mice. Genes. Dev. 1991, 5:1513-1523.
- 30 8. Skarnes, W.C., et al.: A Gene Trap Approach in Mouse Embryonic Stem Cells: The lacZ Reporter is Activated by Splicing, Reflects Endogenous Gene Expression, and is Mutagenic in Mice. Genes Dev, 1992, 6:903-918: describes gene trapping that results in activation of lacZ by splicing to endogenous exons and production of a fusion protein whose expression pattern mimics that of the
- 35 endogenous gene. The resulting integration and fusion is mutagenic. Using 5' RACE, the endogenous gene activated

- 5 -

with three lacZ-based gene-trap insertions was cloned and the effectiveness of the En-2 splice acceptor site was demonstrated. For two insertions, the pattern of lacZ expression in embryos was shown to match the normal  
5 distribution of endogenous transcripts. Two of the three insertions tested cause phenotypic abnormalities in mice. One of those was an insertion into a novel gene expressed widely during development that causes perinatal death in homozygous animals. The other is an insertion into a  
10 zinc-finger gene expressed in neural cells that results in mild growth retardation after birth.

9. Von Melchner, H., et al.: Selective Disruption of Genes Expressed in Totipotent Embryonal Stem Cells. Genes.  
15 Dev. 1992, 6:919-927: where sequences upstream of nine retroviral promoter-trap insertions were cloned using inverse PCR. Flanking probes from five ES cell lines detected transcripts, and one clone is identified as the REX-I transcription factor. Two of four lines transmitted  
20 to the germline caused embryonic-lethal phenotypes.

10. Sheridan, U., et al.: Transcriptionally Active Genomic Regions are Preferred Targets for Retroviral Integration. Mol. Cell. Biol. 1990, 64:907-912.

25 11. Vijaya, S., et al.: Acceptor Sites for Retroviral Integrations Map Near DNase 1-Hypersensitive Sites in chromatin. J. Virol. 1986, 60:683-692.

30 12. Rohdewold, H., et al.: Retrovirus Integration and Chromatin Structure: Moloney Murine Leukemia Proviral Integration Sites Map near DNase I Hypersensitive Sites. J. Virol 1987, 61:336-343.

35 13. Boggs, S.S., et al.: Efficient Transformation and Frequent Single Site, Single Copy Transcription of DNA can



- 6 -

be Obtained in Mouse Erythroleukemia Cells Transformed by Electroporation. Exp Hematol 1986, 149:988-994.

5 14. Soininen, R., et al.: The Mouse Enhancer Trap Locus I (Etl-1): A Novel Mammalian Gene Related to Drosophila and Yeast Transcriptional Regulator Genes. Mech Dev 1993, 39:111-123.

10 15. Niwa, H., et al.: An Efficient Gene-Trap Method using Poly A Trap Vectors and Characterization of Gene-Trap Events. J. Biochem 1993, 113:343-349.

15 16. Breindl, J.K., et al.: Retrovirus-Induced Lethal Mutation in Collagen I Gene of Mice is Associated with Altered Chromatin Structure. Cell 1984, 38:9-16.

20 17. Jahner, D. and Jaenisch, R.: Retrovirus-Induced de Novo Methylation of Flanking Host Sequences Correlates with Gene Inactivity. Nature 1985, 315:594-597.

18. Kratochwil, K.: Retroviral-Induced Mutation in Mov 13 Mice Affects Collages I Expression in a Tissue-Specific Manner. Cell 1989, 57:807,816.

25 19. Goebel, M.G. and Petes, T.D.: Most of the Yeast Sequences are Not Essential for Cell Growth and Division. Cell 1986, 46:983-922.

30 20. Wilson, C., et al.: P-element Mediated Enhancer Detection: An Efficient Method for Isolating and Characterizing Developmentally Regulated Genes in Drosophila. Genes. Dev. 1989, 3:1301-1313.

35 21. Wood, S.A., et al.: Non-Injection methods for the Production of Embryonic Stem Cell-Embryo Chimeras. Nature 1993, 365:87-89: describes time-saving methods for

- 7 -

generating ES cell derived chimeras by morulae aggregation. These can be used to more easily carry out a prescreen based on embryonic expression of the reporter.

- 5     22. Doetschman, T.C.: The in Vitro Development of Blastocyst-Derived Embryonic Stem Cell lines: Formation of Visceral Yolk Sac, Blood Islands and Myocardium. J. Embryo. Exp. Morph. 1985, 97:27-45.
- 10    23. Risau, W., et al.: Vasculogenesis and Angiogenesis in Embryonic-Stem-Cell Derived Embryoid Bodies. Development 1988, 102:471-478.
- 15    24. Wiles, M.V. and Keller, G.: Multiple Hematopoietic Lineages Develop from Embryonic Stem (ES) Cells in Culture. Development 1991, 111:259-267.
- 20    25. Rossant, J., et al.: A large Scale Gene Trap Screen for Insertional Mutations in Developmentally Regulated Genes in Mice. Genetics 1995, 139:889-899: describes the use of a gene trap vector to mutagenize ES cells and the screening of ES clones by injection into blastocysts and assaying for reporter gene expression in 8,5 dpc chimeric mouse embryos.
- 25    26. Thompson, et al.: Gene Trapping in Differentiating Cell Lines: Regulation of the Lysosomal Protease Cathepsin B in Skeletal Myoblast Growth and Fusion: describes the use of a retroviral promoter trap vector in the myoblast cell line C2C12, to identify and isolate skeletal muscle specific genes.
- 30    27. Shiria, et al.: A Gene Trap Strategy to Identify Genes That Are Expressed in the Developing Mouse Nervous System. Zoological Science 1996, 13:277-283: describes use of a gene trap vector called pSneoNlacZA in ES cells.
- 35

ES clones were allowed to differentiate *in vitro* in a suspension culture system into neurons, neuro-glia precursors cells. Neuronal cells were identified by using antibodies reactive against neuron specific proteins.

- 5 Three clones that were immunohistochemically positive and  $\beta$ -gal positive were identified.

28. Imai, et al.: Cloning of Retinoic Acid Induced Gene, GT1, in Embryonal Carcinoma Cell Line P19: Neuron Specific Expression in Mouse Brain. Molecular Brain Research. 1995, 31:1-9: describes the use of a gene trap vector in mouse P19 embryonal carcinoma cell line which can be reproducibly differentiated to neurons and glial cells upon treatment with retinoic acid. Assay for up or down  
10 regulation of  $\beta$ -gal activity and immunohistochemistry showed localization in neurons.  
15

29. Forrester, et al.: An Induction Gene Trap Screen in Embryonic Stem Cells: Identification of Genes that Respond to Retinoic Acid *in vitro*. Proc. Nat. Acad. Sci. USA 1996, 93:1677-82: where a gene trap vector was used in ES cells and treated with retinoic acid, with a screen for genes that are induced or repressed upon retinoic acid exposure.  
20

30. Hill, D.P. and Wurst, W. (1993): Screening for Novel Pattern Formation Genes Using Gene Trap Approaches, Methods in Enzymology 225:664-681.  
25

31. Kim, D.G., et al. (1992): Construction of a Bifunctional mRNA in the Mouse by Using the Internal Ribosomal Entry Site of the Encephalomyocarditis Virus. Molecular and Cellular Biology, 12: 3636-3634: describes construction of vectors comprising a promoter driven selector (eg. neo) followed by EMCV 5' non-translated region and either lacZ or cat, and transfection of murine  
30 ES cells with the vectors. The IRES of the EMCV permitted  
35

- 9 -

more efficient translation of the reporter in resulting chimeric embryos which also expressed the selection gene.

32. Chowdhury, K. et al. (1997): Evidence for the Stochastic Integration of Gene Trap Vectors into the Mouse Germline. Nucleic Acids Research, 25: 1531-1536: describes construction of a gene trap vector comprising an EN-2 splice acceptor followed by an IRES sequence and B<sub>geo</sub> (lacZ reporter fused with neo selector). Murine ES cells were transfected and neomycin resistant colonies were monitored for  $\beta$ -galactosidase activity indicative of lacZ expression Molecular cloning of trapped exons was carried out using 5'-RACE.
33. D.P. Hill and W. Wurst (1993): Screening for Novel Pattern Formation Genes Using Gene Trap Approaches; Methods in Enzymology 225: 664-681.
34. G. Friedrich and P. Soriano (1993): Insertional Mutagenesis by Retroviruses and Promoter Traps in Embryonic Stem Cells; Methods in Enzymology 225: 681-701.
35. W.C. Skarnes (1993): The Identification of New Genes: Gene Trapping in Transgenic Mice; Current Opinion in Biotechnology 4: 684-689.

Regardless of the model, the process of identifying and manipulating tissue specific genes requires elaborate screening procedures to link a mutation to a particular spacial/temporal scheme or event whereby the mutation is detected in the relevant tissue. It is therefore desirable to make screening and manipulation of new spacial/temporally regulated genes in all eucaryotic models more efficient.

Summary of Invention

This invention makes use of known genes whose expression is restricted to specific tissue, tissues or  
5 specialized cells ("restricted expression") to facilitate identification and manipulation of new genes and their associated transcription control elements which have similar patterns of expression.

10 Accordingly, this invention provides a method of detecting a target gene having restricted expression in a eucaryotic organism, which comprises the steps of:

15 (i) transforming a eucaryotic cell with a DNA sequence encoding a first indicator component under the control of a promoter having restricted expression;

20 (ii) transforming the cell of (i) or a descendent of the cell of step (i), by operably integrating into the cell's genome DNA lacking a promoter but which comprises a sequence encoding a second indicator component;

25 (iii) producing tissue or specialized cells from the cell of (ii); and

30 (iv) monitoring the tissue or specialized cells of (iii) for a detectable indicator resulting from both the first and second indicator components.

This invention also provides a method of obtaining a gene, a part of a gene, transcription control element or other nucleotide sequence, having restricted expression  
35 which includes isolating endogenous DNA flanking of the sequence encoding the second indicator component from a

- 11 -

cell or descendent of a cell prepared as described above in which the detectable indicator is found. This invention also provides a method of modifying the gene, transcriptional control element or other nucleotide  
5 sequence obtained as described above which includes modification of the endogenous DNA which flanks the coding sequence of the second indicator component.

This invention also provides a method of providing a  
10 eucaryotic organism producing a detectable indicator in a specialized cell or tissue of the organism which includes growing a multi-cellular eucaryotic organism from a cell or cell descendent from a cell prepared as described above, in which the detectable indicator is found. The organism may  
15 also express in the specialized cell or tissue, the product of heterologous DNA expressed with DNA flanking of the second indicator component of the detectable indicator.

This invention makes use of a gene entrapment strategy  
20 whereby a detectable indicator is detected when more than one component of the indicator is expressed in the same cell. One method of this invention involves stable and operable insertion of a nucleic acid construct which includes one indicator component of the complementation  
25 trap under the control of a known promoter having restricted expression into the genome of the cell. This is followed by further transformation of the cell, or a cell derived from the previously transformed cell, by insertion into the cell's genome of a trap vector which includes a  
30 DNA which encodes a second indicator component. Insertion of the trap vector into an endogenous gene may result in the transcription of both the endogenous gene and the second indicator component under control of the endogenous promoter and subsequent translation of the second  
35 component. If the trap vector integrates into an endogenous gene which is expressed in the same cell or

- 12 -

tissue type as the first indicator component, a indicator resulting from the combination of the first and second indicator components may be detected. Thus, this invention allows one to distinguish target eukaryotic genes which are expressed in the same cell or tissue type as the promoter controlling the first component of the entrapment system. This system, as embodied by this invention is termed a "complementation trap".

10           This invention provides a DNA construct comprising a splice acceptor upstream of a sequence encoding a component of a detectable indicator according to this invention. The component may be, for example, an enzyme fragment or subunit, or an enzyme functional in a pathway leading to production of a detectable indicator. This invention also provides a DNA construct comprising a promoter having restricted expression upstream of a sequence encoding a component of a detectable indicator as described above.

20           This invention also provides a first DNA construct comprising a splice acceptor upstream of a sequence encoding a first peptide selected from the group consisting of an alpha peptide and an omega peptide of  $\beta$ -galactosidase ( $\beta$ -gal), wherein the first peptide lacks  $\beta$ -gal activity but is capable of alpha complementation to produce active  $\beta$ -gal. This invention also provides a eucaryotic cell and a non-human, multi-cellular eucaryotic organism having operably and stably incorporated into its genome, the first DNA construct described above. This invention also provides a kit including the first DNA construct and, a second DNA construct comprising a promoter having restricted expression upstream of a sequence encoding a second  $\beta$ -gal peptide selected such that the second peptide is capable of alpha complementation with the first peptide. This invention also provides a eucaryotic cell and a

- 13 -

non-human, multi-cellular eucaryotic organism having operably and stably incorporated into its genome the first DNA construct and which also expresses the second DNA construct.

5

Trap vectors useful for this invention, including the above-described first DNA construct, may also contain additional elements such as an internal ribosome entry sequence (IRES) upstream of the second indicator component (eg. the first peptide) or, sequences that allow for directional integration of a heterologous gene, such as a recognition site for site specific recombination (eg. lox).

This invention may be used to identify tissue or cell type specific genes. For example, a nucleic acid construct containing the coding sequence of a first indicator component under control of a known tissue specific promoter is "seeded" into cells which may be made to differentiate or whose nuclear material may be incorporated into cells which are capable of differentiation. The second component is then introduced into a cell having the "seeded" construct, by means of the trap vector. The resulting cells, or cells derived from those cells (eg. progeny), are then induced to differentiate (for example by addition or withdrawal of a chemical inducer/repressor) or allowed to spontaneously differentiate. The cells are then screened for activity of the indicator which will occur in the cell or tissue type in which the promoter is functional.

This invention is particularly useful for screening cell or tissue specific genes or transcriptional control elements such as promoters and enhancers, in any animal from which embryonic stem (ES) cell lines may be obtained. The ES cell is subjected to the complementation trap process described above. The ES cells are then allowed to differentiate *in vitro* and cells are screened for the



- 14 -

indicator. ES cells demonstrating expression of the indicator may be introduced into a blastocyst to produce an animal which will exhibit the same pattern of expression. Where introduction of the trap vector results in disruption of the target gene, the animal resulting from the mutated ES cells will be useful as a "knock-out" animal useful for study of the target gene. Alternatively, location of the trap vector into the endogenous gene will provide means for subsequent disruption of the target gene for production of "knock-out" animals. The trap vector of this invention may be used as a means for locating, cloning, sequencing, and further mutation of the target gene or promoter or enhancer sequences associated with the target gene.

This invention will make new transcriptional control elements available for use in making new transgenic animals displaying cell, tissue or organelle specific expression of transgenes. Promoters made available by use of this invention may themselves be made to control the first indicator component in the complementation trap of this invention in a "leap-frog" procedure whereby new genes having the same restriction pattern as the promoter or may be located.

#### Brief Description of Drawings

Figure 1: is a schematic illustrating a DNA construct useful in this invention comprising the myeloid cell specific promoter CD11b controlling the sequence encoding a  $\beta$ -galactosidase alpha peptide terminated by the human growth hormone poly-adenylation signal. Downstream is a selection cassette, which in this case confers resistance to hygromycin driven by the phosphoglycerate kinase promoter.

- 15 -

Figure 2: is a schematic illustrating a DNA construct useful as a trap vector of this invention comprising the mouse En-2 splice acceptor upstream of the coding sequence of the  $\beta$ -galactosidase omega peptide and a selection cassette for neomycin resistance.

Figure 3: is a schematic illustrating a trap vector of this invention in which a IRES sequence is positioned upstream of the  $\beta$ -gal omega sequence shown in Figure 2.

Figure 4: is a schematic illustrating a trap vector of this invention in which a IRES sequence and a lox site are positioned downstream of the  $\beta$ -gal omega peptide coding sequence shown in Figure 2.

#### Description of Specific Embodiments

The term "eucaryotic organism" in this specification means any multi-cellular eucaryote having cells which are differentiated to specific cell or tissue types and includes plant or animal organisms, including, but not restricted to: Drosophila, nematodes, fish and mammals. The method of this invention may be carried out to transform any eucaryotic cell which is capable of differentiation into tissue or specialized cell types and includes any bi- or multipotent eucaryotic cell as well as a differentiated eucaryotic cell whose nuclear material may be transplanted to a bi- or multipotent cell. An example of the latter situation is where differentiated cells are transformed according to the method of this invention and whose nuclear material is subsequently placed in a enucleated ovum or similar vehicle which is then caused to become bi- or multipotent and thus capable of differentiation. Particularly suitable for this invention are totipotent cells such as ES cells.

- 16 -

The term "restricted expression" in this specification means the restriction of a transcription control element (such as a promoter or an enhancer) or the restriction of expression of a gene, such that the aforesaid function or expression occurs in a particular tissue or cell type in a eucaryotic organism. Thus a gene or transcription control element having "restricted expression" is a tissue or cell specific gene or control element.

10 The "detectable indicator" of this invention is a detectable event which results from the expression of more than one indicator component in a cell.

15 This invention may be used to isolate, characterize, and modify genes that are differentially expressed. Tissue or cell specific genes may be located by using any tissue or cell specific promoter to drive the first indicator component of the complementation trap system. An example of this invention used to identify genes that are expressed in myeloid cells of the hemopoietic system, would be to make use a known myeloid cell/tissue specific promoter such as CD11b to drive the expression of the first indicator component of the complementation trap system. Examples of other tissue restricted promoters are listed below but this invention may be carried out using any promoter with restricted expression:

Neural: Neuron specific RI $\beta$  sub unit of cAMP-PK promoter, Tryptophan Hydroxylase promoter, Neural specific enolase promoter, Tyrosine hydroxylase promoter, T $\alpha$ 1  $\alpha$ - tubulin promoter;

Lung:  $\alpha$ 1 collagen gene promoter, rat clara cell 10 protein PROMOTER, human surfactant protein SP-C promoter, preproendothelin promoter;

- 17 -

Liver: human apolipoprotein E promoter;

Heart: alpha B crystallin promoter, murine alpha myosin heavy chain promoter;

5

Thymus: lck proximal promoter;

T cells: CD2 promoter, CD4 promoter, CD3 promoter;

10

B cells: IGE $\mu$ , CD19 promoter;

Osteoclast - and osteoblast specific promoter: Mouse pro- $\alpha$ 1(I) promoter, Tartrate Resistant Acid Phosphatase (TRAP) promoter, CD11b promoter.

15

One example of a detectable indicator that may be used in this invention occurs as the result of the well-known phenomenon of alpha complementation of  $\beta$ -galactosidase ( $\beta$ -gal) fragments. The  $\beta$ -gal enzyme can be divided into two peptides called alpha and omega.  $\beta$ -gal enzyme activity is present only when both alpha and omega peptides are present in the same cell. The alpha and the omega peptide alone show no detectable enzymatic activity.  $\beta$ -galactosidase enzyme activity can be detected by using commercially available enzyme substrates such as X-gal<sup>TM</sup> which turns blue upon hydrolysis by  $\beta$ -galactosidase. Other substrates such as Galacton-plus<sup>TM</sup> (Clontech) produce light upon enzymatic cleavage allowing for detection using a luminometer while other substrates produce fluorescent products detectable by flow cytometry or fluorescence microscopy. The Galacto-star<sup>TM</sup> kit (Tropix, Inc.; Bedford, M.A., U.S.A.) which provides a chemiluminescent assay is particularly useful for preferential detection of  $\beta$ -gal over endogenous mammalian  $\beta$ -gal activity.

35

- 18 -

Alpha complementation of  $\beta$ -gal may be accomplished in eucaryotic cells, including yeast and mammalian cells; see: Mohler, W.A. and Blau, H.M. 1996. Gene Expression and Cell Fusion Analyzed by lacZ Complementation in Mammalian Cells.

- 5 Proc. Natl. Acad. Sci. 93:12423-12427; and Moosman, P. and Rusconi, S. (1996). Alpha Complementation of lacZ in Mammalian Cells. Nucleic Acids Res. 24:1171-1172.

10 In order to identify genes that are expressed in myeloid cells, one may use the CD11b promoter to drive expression in myeloid cells of a sequence encoding one of the  $\beta$ -gal peptides (eg. the alpha fragment comprising about 85 or more N-terminal amino acids of  $\beta$ -gal). The trap vector would include a splice acceptor sequence, a sequence  
15 encoding an omega fragment of  $\beta$ -gal (eg. inactive  $\beta$ -gal peptide lacking a N-terminal portion of  $\beta$ -gal), and optionally, an IRES sequence and a lox site for directed integration of heterologous genes. The trap vector may optionally contain a second reporter system to identify and  
20 characterize the endogenous gene expression pattern. The trap vector may also contain a selectable marker cassette. Another approach would be to introduce the first indicator component to be under control of an endogenous promoter having restricted expression endogenous gene via homologous recombination. For example, in order to obtain expression  
25 in early immature B lymphocytes, a sequence encoding the first indicator component may be introduced by homologous recombination into the CD 19 gene in a mouse ES cell germline such that the expression of the indicator component is under the control of the CD 19 gene (eg.  
30 see: Rickert, R.C. et al. (1997): B Lymphocyte-specific, Cre-mediated Mutagenesis in Mice; Nucleic Acids Research, 25:1317-1318).

- 35 Stable lines of ES cells bearing the tissue restricted promoter driving the alpha component are generated and

- 19 -

tested for appropriate tissue restricted expression. Mutations are then introduced in the mouse genome by random integration of the omega peptide trap vector. Since the trap vector has a splice acceptor sequence fused to the omega component, integration of the trap vector into a gene intron results in splicing omega mRNA into the transcript of the endogenous gene and ultimately, expression of a fusion protein comprising of a portion of the endogenous protein and the omega subunit. Where a IRES is placed upstream of the omega component, the omega peptide is translated without being fused to the endogenous protein.

Individual integration/mutational events are propagated and replica plated. One fraction of the cells are allowed to undergo in vitro differentiation and are assayed for the indicator. If both  $\beta$ -gal subunits are expressed in the same cell, the indicator is detected whereas the components expressed individually in cells will not be detected. Thus, this procedure identifies integration/mutational events into genes that are expressed in the same given tissue cell type that is defined by the known tissue restricted promoter driving the first component.

Target genes into which the gene trap has integrated can be cloned and sequenced, for example, by 5' RACE PCR. Undifferentiated ES cells can be used to generate mice mutated for the respective gene. The endogenous tissue restricted promoter of the target gene can be characterised and heterologous genes can be inserted into the site by homologous recombination or site directed recombination, thus allowing the heterologous gene to be driven by the newly identified endogenous tissue restricted promoter.

A "leap-frog" procedure may be employed whereby the tissue specific promoter of the target gene may become the

- 20 -

"known" promoter driving expression of the first indicator component. The example employing  $\beta$ -gal complementation described above may be accomplished regardless of which  $\beta$ -gal peptide is expressed in the target gene or under control of the known tissue specific promoter. Thus, cells when containing both  $\beta$ -gal peptide inserts have been shown to result in restricted expression of both peptides upon differentiation, a stored sample of the original transformed cells may be manipulated to remove or disrupt expression of the peptide whose expression is controlled by the "known" tissue restricted promoter. For example, the DNA which encodes the first indicator component under control of the known promoter may be flanked by lox sequences which permit the excision of the sequence encoding the first indicator from the genome with Cre recombinase. A trap vector may then be introduced comprising a splice acceptor and a coding sequence equivalent to that which has been removed or disrupted. Mutational events which result in expression of the new trap vector are detected because of the combination of the indicator component expressed as a result of the first introduced trap vector, plus the component expressed as a result of the second trap vector. Thus, genes having a pattern of expression similar to the first target gene may be located even if the pattern of expression differs from that of the original "known" promoter.

The foregoing description illustrates embodiments of this invention in which the first component is driven by a known promoter and the detectable indicator results from enzymatic complementation of proteins or peptides expressed from the first and second indicator component coding sequences. This invention may be carried out using any detectable gene products which exhibit intra-cistronic complementation. Other peptides which exhibit enzymatic complementation may be employed in this invention in the

- 21 -

same manner as alpha and omega fragments of  $\beta$ -gal. Alternatively, the detectable indicator components may be subunits of a detectable protein which subunits are expressed from different genes or coding regions. An  
5 example would be the subunits of bacterial luciferase.

The following are further examples of different detectable indicators and components thereof which may be used in this invention:

10

(a) Transcriptional activation (two hybrid system): the detectable indicator results from transcription of a reporter gene which requires the presence of two genetic components; a DNA binding subunit and a transcriptional  
15 activating subunit. Both components need to be present in the same cell in order for expression of the reporter gene to occur and subsequent detection of the reporter gene product.

20

(b) Transcriptional activation (genetic recombination dependent): the detectable indicator results from transcription and expression of a reporter gene regulated by a tissue specific promoter which is conditional upon genetic recombination controlled by expression of a  
25 recombinase enzyme. For example, a stuffer DNA sequence (flanked by lox sequences) which prevents efficient transcription or expression of a reporter gene is removed by recombination that is mediated by a Cre recombinase enzyme allowing for expression of the reporter gene and  
30 subsequent detection of its product. Alternatively, a recombination event may be required to juxtapose the promoter/enhancer sequence with the reporter gene in the correct orientation to allow for the efficient expression of the reporter gene.

35



- 22 -

(c) Enzyme pathway: the detectable indicator is a product generated by the sequential action of two enzymes on a substrate. Alternatively, the detectable indicator may result from products produced by the action of two enzymes which interact in such a way as to generate a detectable signal. Alternatively, the detectable indicator results from activity of a first enzyme which is regulated by the activity of a second enzyme, (for example: enzymatic activity of first enzyme is dependant on a post translational modification mediated by a second enzyme, such as proteolytic activation, glycosylation or phosphorylation etc.).

(d) Selection/screening system: a selectable marker such as an antibiotic resistance gene is driven by a tissue specific promoter and a second reporter gene is used in a trap vector. The cells are induced to differentiate and are subsequently placed under selection conditions that allow for the survival of only those cells expressing the selectable marker. Those cells are then screened for the expression of the second reporter.

(e) Co-expression of two reporter genes: one reporter is driven by a "known" tissue specific promoter and the second reporter is used in a trap vector. Differentiated cells are screened for expression of both reporter genes in the same cell.

Examples of suitable reporter genes that may be employed in the above-described examples are:  $\beta$ -galactosidase, alkaline phosphatase, blue fluorescent protein, green fluorescent protein (GFP),  $\beta$ -glucuronidase (GUS), Cre recombinase, Flp recombinase, luciferase, and their cell surface protein with antibodies that can detect its expression. Suitable selectable markers that may be used are: Neo- (neomycin phosphotransferase), Hvgro-

- 23 -

(hygromycin  $\beta$ -phosphotransferase), Puro- (puromycin n-acetyltransferase *pac*), HisD- (histidinol dehydrogenase), and Gpt- (xanthine/guanine phosphoribosyl transferase).

5        Examples of ES cell lines which may be used in this invention are: porcine (eg. US Patent 5523226 Transgenic Swine Compositions and Methods); murine (eg. D3, R1, CGR8, AB1 ES cell lines); primate (eg. rhesus monkey); rodent; marmoset; avian (eg. chicken); bovine; rabbit; sheep; and  
10       horse.

         A wide variety of cells may be targeted by the trap vectors of this invention, including stem cells, pluripotent cells such as zygotes, embryos, ES cells, other  
15       cells such as lymphoid and myeloid stem cells, neural stem cells, transformed cells such as tumour cells, infected cells differentiated cells, etc. The cells may be targeted in culture or *in vivo*. Vectors may be introduced into the cells by any convenient means. For example, with cells in  
20       culture, conventional techniques such as transfection (eg. lipofection, calcium phosphate precipitation, electroporation, etc.), microinjection, viral infection etc. may be used. For cells within the organism, introduction may be mediated by virus, liposome, or any  
25       other convenient technique.

         Examples of different trap vectors for use in this invention are as follows:

30       Gene trap: a promoterless reporter gene component carrying a splice acceptor sequence at the 5' end. Each vector will splice in the correct reading frame in 1 of 3 possible reading frames. The vector should integrate in to an intron sequence of a gene to result in a fusion  
35       transcript and a fusion protein product. The 5' sequence of the fusion transcript is encoded by the endogenous gene

- 24 -

and the 3' sequence is encoded by the gene trap vector. Three gene trap vectors can be created for splicing into each of the three reading frames. The reporter gene lacks ATG translation start signal.

5

Gene trap (SA- IRES- reporter): a promoterless reporter gene containing a proper translation initiation sequence having a splice acceptor sequence (SA) followed by a IRES at the 5' end.

10

Exon trap: a reporter gene component lacking a splice acceptor and a mammalian initiator codon. Integration of this vector into an exon in the proper translational frame results in the production of a fusion protein.

15

Enhancer trap: reporter gene lacking a promoter but having a "minimal promoter" sequence encoding a TATA box and a transcriptional initiation site. These may be used to locate a target gene affected by an enhancer with restricted expression. The indicator must be monitored for enhanced expression in a particular cell type.

20

Promoter trap: promoterless reporter gene with appropriate translation initiation sequence. Insertion into an intron would not result in translation due to RNA processing. Integration immediately proximal to an endogenous promoter is required in order to have appropriate expression.

25

A splice acceptor (SA) includes the 3' end of an intron and the 5' end of an exon as described by Alberts, B. et al. at p. 373 of Molecular Biology of the Cell (1994), 3rd ed. Garland Publishing, N.Y. Splice Acceptors comprise a polypyrimidine tract followed by a nucleotide (N), followed by T or C and AG (3' intron portion), followed by at least G or A (5' exon portion). Examples

30

35

- 25 -

are the murine En-2 splice acceptor and the splice acceptors from human  $\beta$ -globin and rabbit b-globulin.

The following examples are offered by way of illustration of the invention and not by way of limitation.

#### Example 1

Complementation trap vectors may be developed based on the alpha complementation of  $\beta$ -galactosidase.

#### Vectors

Figure 1 illustrates a CD11b alpha vector. The alpha subunit of beta-galactosidase is obtained by polymerase chain reaction (PCR) amplification using the following oligos from the pCMV  $\beta$ -galactosidase plasmid: oligo 1 corresponds to the polylinker sequence 5' of  $\beta$ -gal (5'AACTGCAGTACCCGCGGCCGC3' SEQ ID NO:1) and the oligo 2 introduces stop codons at a position corresponding to amino acid 85 of the E.coli lacZ sequence: (5'AACTGCAGTTATTACTCAGGAAGATCGCACTCCAGC3' SEQ ID NO:2). The PCR fragment is subcloned into pBluescript™. The alpha subunit is then subcloned into the Bam HI site of the CD11b expression cassette containing the CD11b promoter and the human growth hormone mini gene and polyadenylation signal described in: Dzienni, S., et al. (1995) The CD11b Promoter Directs High-Level Expression of Reporter Genes in Macrophages in Transgenic Mice. Blood 85:319-329. The CD11b alpha vector also contains a pPGK Hygro pA cassette allowing for selection with hygromycin. The alpha fragment was also subcloned into the CMV promoter expression cassettes (Clontech).

The omega trap vector illustrated in Figure 2, is a derivative of pGT4.5 (Gossler et al., 1989 [supra]). The

- 26 -

DNA fragment beginning at the unique BglIII in the polylinker sequence between the En-2 splice acceptor sequence and the beginning of the  $\beta$ -gal sequence up to the unique ClaI site within the  $\beta$ -gal sequence from pFT4.5 is replaced by a PCR fragment amplified from pCMVbgal using the following oligos which delete the first 41 amino acids from the N-terminal sequence of  $\beta$ -galactosidase resulting in the  $\beta$ -galactosidase sequence to begin at amino acid 42 of the E.coli  $\beta$ -galactosidase sequence to the unique ClaI site in that sequence. Oligo 1 (5'CGGGATCCCAAGATCTGGGCCCCGCACCGATCGCCCTTCC<sup>3</sup>' SEQ ID NO:3); Oligo 2 (5'CGGGATCCATCGATAATTTACCGCCG<sup>3</sup>' SEQ ID NO:4). PCR product is digested with BglIII and ClaI and is directly inserted into the BglIII-ClaI fragment of pGT4.5 vector. Three forms of this vector can be created; each resulting in a fusion in one of the three transcriptional reading frames.

Figure 3 illustrates an omega trap vector with the IRES sequence from EMCV (Clontech) inserted between the En-2 splice acceptor and the omega subunit. In this case, translation of the omega subunit will be independent of the endogenous translation initiation codon and start at the ATG codon present in the IRES sequence. This IRES sequence has been shown to work in all tissues and does not have any tissue specificity for IRES function. Other IRES suitable for use in vector of this invention are known and are derived from various viral sources including: EMCV, poliovirus, picornavirus, Hepatitis C virus, HTLV-1, Friend murine leukemia virus, Moloney murine leukemia virus, Theiler's murine encephalomyelitis virus, aphthovirus, Hepatitis A virus, ECHO virus, rhinovirus, enterovirus, cardiovirus, and pestivirus.

Figure 4 illustrates an omega trap vector with a IRES sequence followed by a lox7 site between the omega gene and

- 27 -

the poly adenylation signal. This example may also be carried out using CD11b to drive the omega subunit and a trap vector comprising the alpha subunit.

5           The N terminal sequence of Neo to the unique Bal I site in Neo is fused to the omega fragment of  $\beta$ -galactosidase starting at the unique FspI site in  $\beta$ -galactosidase in the trap vectors illustrated in Figures 2-4. The fusion protein is driven by the Herpes  
10   thymidine kinase promoter and polyoma enhancers and has the SV40 polyA signal.

#### $\beta$ -gal Complementation

15           To test whether the omega fragment as a fusion protein is capable of complementation with the alpha fragment, vectors were constructed to express a portion of the Neo gene fused to the  $\beta$ -gal omega peptide described above under control of the human cytomegalovirus immediate - early gene  
20   (CMV) promoter. As a fusion with the neo gene product, the omega peptide was found to be capable of complementing with the alpha fragment in 293 kidney cell line. Transient transfection by Superfection<sup>TM</sup> (Qiagen) of 293 cells with  
25   fragment alone showed background levels of enzyme activity whereas the combination of the alpha and omega subunits resulted in detectable enzyme activity by the luminescent  $\beta$ -galactosidase Genetic Reporter System II<sup>TM</sup> from Clontech.

30           The alpha subunit prepared as described above was excised from pBluescript<sup>TM</sup> using NotI and subcloned into the NotI site of the pIRES1hyg expression vector (Clontech) resulting in a bicistronic expression vector, pCMValpha, containing the human cytomegalovirus (CMV) major immediate  
35   early promoter/enhancer driving the expression of the alpha subunit followed by an IRES Hygromycin (which predisposes

- 28 -

virtually every hygromycin resistant transfected cell to express the alpha gene). The mCMValpha vector and the omega trap vector containing the IRES sequence, pGT omega IRES (as described above) were used to demonstrate  $\beta$ -gal complementation in ES cells. R<sub>1</sub> ES cells (Nagy, A. [supra]) were electroporated with the HindIII linearized pCMValpha plasmid DNA. Clones were then selected in the presence of 100 $\mu$ g/ml Hygromycin. A polyclonal hygromycin resistant pool was expanded and then electroporated with HindIII linearized pGT omega IRES DNA. Clones were selected with 180 $\mu$ g/ml G418. Individual colonies were picked and transferred to 96 well plates. Individual clones were then analyzed for  $\beta$ -gal activity using the  $\beta$ -gal genetic reporter II Kit from Clontech. One in 50 clones showed complementation activity in ES cells.

#### ES Cell Culture, Selection and Gene Insertion

Murine R1 ES cells from A. Nagy [Proc. Nat. Acad. Sci. U.S.A. (1993) 90, 8424-8428] may be grown on Primary Embryonic Fibroblast feeder layers or on gelatinized dishes in the presence of 1000 U/ml murine leukemia inhibitory factor (LIF), ESGRO<sup>TM</sup> (GIBCO BRL). Selection conditions are: 150  $\mu$ g/ml G418, 1.0  $\mu$ g/ml puromycin, 110  $\mu$ g/ml Hygromycin B. 2 x 10<sup>7</sup> R1 cells may be electroporated with 100 $\mu$ g linearized DNA in 0.8 ml PBS at 500 $\mu$ F and 240V with a BioRad Gene Pulser<sup>TM</sup> at room temperature.

The ES cells may be electroporated with CD11b promoter driving the alpha subunit and selected with hygromycin to obtain stable clones. Clones would then be selected and characterized by the expression pattern of the alpha subunit. Clones are isolated which express the alpha subunit in myeloid cells. The omega trap vector would then be electroporated into CD11b alpha ES cells. Cells would then be plated into 96 well plates to obtain approximately

- 29 -

10 Neo resistant clones per well with 150  $\mu\text{g/ml}$  G418. Clones should be replica plated in duplicate. One set is frozen and one set allowed to differentiate and assayed for  $\beta$ -gal activity. Positive wells would be identified and individual cells subcloned and assay is repeated on individual clones. The following protocol may be used:

Picking of individual ES cell colonies:

- 10 1) plate out cells at low dilution;
- 2) grow for 9-12 days allowing individual cells to grow into individual colonies;
- 3) pick individual colonies in 5 to 10  $\mu\text{l}$  volume using a P20 Gilson Pipetman<sup>TM</sup>;
- 15 4) transfer colonies into 50  $\mu\text{l}$  Trypsin/EDTA (Gibco/BFL) in a 96 well round bottom plate;
- 5) incubate for 5 min at RT;
- 6) add 50  $\mu\text{l}$  fresh serum containing ES cell media
- 7) disrupt colonies to single cell suspension by pipetting up and down; and
- 20 8) replate cells on gelatinized tissue culture plates and add fresh media as necessary.

Freezing ES cells in 96-well plates:

- 1) aspirate off media;
- 25 2) replace with 30  $\mu\text{l}$  freezing media per well. (Freezing media contains: 50% serum, 10% DMSO, 40% DMEM, 1000U/ml LIF); and
- 3) transfer plate into -70°C freezer in a styrofoam box.

30 Thawing ES cells in 96 well plates:

- 1) add 100  $\mu\text{l}$  prewarmed ES cell media per well;
- 2) incubate cells at 37°C 5% CO<sub>2</sub> for 6-8 hours; and
- 3) replace with fresh media.

35 Expression patterns of the alpha subunit may be characterized by in situ hybridization or



- 30 -

immunohistochemistry using a monoclonal or anti-peptide antibody raised against the alpha peptide; immunofluorescence dual labelling with anti-alpha peptide and anti-MAC-1 (CD11b); or, by transfecting cells with CMV promoter driving the expression of the omega fragment and detecting  $\beta$ -gal activity.

In an alternative procedure, the ES cells would be electroporated with CD11b promoter driving expression of alpha subunit and selected with hygromycin to obtain stable clones. Several clones would be identified and the expression pattern of the alpha subunit characterized in order to isolate clones which express the alpha subunit in myeloid cells. The omega trap vector containing IRES and lox71 would be electroporated into the CD11b alpha ES cell. The cells would then be plated in a 96 well plate to obtain approximately 10 Neo resistant clones per well. Clones would then be selected with 150  $\mu$ g/ml G418 and replica plated in duplicate. One set would be frozen and one set allowed to differentiate and assayed for  $\beta$ -gal activity. Positive wells would be identified and individual cells subcloned with the assay being repeated on individual clones. Heterologous DNA would then be introduced into trapped events by co-electroporation of a transgene as a circular plasmid containing a single mutant lox (lox66) site with CRE expression cassette for transient expression of CRE. Stable integration of the transgene would be determined by selection for a resistance gene found on transgene vector (eg. Araki et al., 1997 Targeted Integration of DNA Using Mutant lox Sites in Embryonic Stem Cells. Nucleic Acids Research 25,868-872).

Preferential differentiation of ES cells to obtain macrophage cells may be accomplished by known procedures, including those described by: Lieschke, G.J. and Dunn, A.R. Development of Functional Macrophages from Embryonal

- 31 -

Stem Cells In Vitro. (1995) Experimental Hematology 23(4):328-334. Alternatively, chimeric embryos and resulting chimeric mice may be obtained by injection of the ES cells into blastocysts, eg. C57BL/6 blastocysts.

5

#### 5' RACE Cloning

5' Rapid PCR amplification of cDNA ends (RACE) may be carried out as described by Skarnes, et al. at (1992) Genes and Development 6, 903-918, to clone a portion of the endogenous gene flanking the omega component insertion. This provides fragments for sequencing and to probe for genes. The source of reagents may be the 5' RACE kit commercially available from Gibco-BRL. An additional round of nested PCR may be performed. Macrophage cells may be enriched by Fluorescent Activated Cell Sorting (FACS) or immuno-magnetic bead purification prior to RNA isolation. PCR products may be subcloned into pBluescript™. In order to confirm the sequences of the trapped exons, 5-10 bacterial colonies should be picked from each line and the isolated plasmid DNAs sequenced by standard double strand sequencing protocols. High throughput solid phase sequencing of 5' RACE PCR product is describe in Townley, D.J. et al. (1997) Rapid Sequence Analysis of Gene Trap Integrations to Generate a Resource of Insertional Mutations in Mice, Genome Research 7:293-298.

#### Choice of Complementation Systems:

The optimal choice of a complementation system will depend on the following criteria: the given target tissue or cell type from which gene trap events are to be identified, the level of expression of endogenous activity of the kind exhibited by the complementation components in the given tissue or cell type, and the ability of the cells

- 32 -

to differentiate in vitro and then dependence on other cell types for growth.

If one targets macrophage cells to identify macrophage specific genes using  $\beta$ -gal complementation, consideration should be given to the fact that macrophage cells display a background level of endogenous  $\beta$ -gal activity. Therefore, the alpha complementation of  $\beta$ -gal may not be the ideal complementation system of choice for macrophage cells since the detection of activity of complemented  $\beta$ -gal may be compromised. The activity of the complemented  $\beta$ -gal can be approximately 25-200 fold weaker than that of wild-type lacZ, as demonstrated in 293 cells and in NIH3T3 cells (Mohler and Blau 1996 [supra]) coexpressing alpha and omega subunits of  $\beta$ -gal.

Because of potential for low activity of complemented  $\beta$ -gal, the most sensitive detection systems (such as assays based on fluorescence use of a luminometer and reagents such as Gatacton-plus<sup>TM</sup>, or those in the Galacto-star<sup>TM</sup> kit) should be used when employing alpha-complementation of  $\beta$ -gal. Steps should be taken using known methods to reduce background  $\beta$ -gal activity such as adjustment of temperature or pH. For tissues which do express endogenous  $\beta$ -gal, it may be advisable to chose an alternate reporter system.

#### Use of Alpha Complementation of $\beta$ -gal in Identification of Neural Specific Genes

30

Alpha complementation of  $\beta$ -gal may be particularly suited for identification of neural specific genes since ES-derived neuronal cells do not display endogenous  $\beta$ -gal activity in vitro. This enzyme complementation system may make use of the rat 1.8 kb neuron-specific enolase promoter (NSE) to identify gene trap events in neuronal

- 33 -

cell restricted genes in the construction of vectors as described in Figure 1 in which the CD11b promoter is replaced with the NSE promoter. The *in vitro* expression profile of the NSE promoter in differentiated ES cells has been previously characterized (Alouani S. et al. (1993). Transcriptional Activity of the Neuron-Specific Enolase (NSE) Promoter in Murine Embryonic Stem (ES) Cells and Preimplantation Embryos. European Journal of Cell Biology. 62(2):324-32; 1993.

10

### Vectors

A vector with NSE driving the alpha subunit of  $\beta$ -gal was produced by introduction of stop codons by ligation of overlapping oligomers into the ClaI site of pNSE $\beta$ gal mode according to Alouani, et al. (1993) [*supra*]. NSE  $\Delta\mu$  as a second vector for neuronal expression of the donor alpha peptide fragment was generated by deleting 553 codons of the lacZ gene in pNSE- $\beta$ gal between two in frame PvuI sites. The omega trap vector with IRES as described in Figure 3 was also used.

Linearized NSE alpha and NSE  $\Delta\mu$  DNA were transfected into R<sub>1</sub> ES cells by co-electroporation with linearized PGKHyg DNA. Clones were selected with 110 $\mu$ g/ml Hygromycin and picked as describe below. Individual clones were characterized for alpha subunit expression by *in situ* hybridization of *in vitro* derived neuronal cells using the differentiation protocol described below. Clones expressing alpha donor genes were subsequently electroporated with the omega IRES gene trap vector and colonies were selected with 150 $\mu$ g/ml G418. Individual clones were picked and replica transferred to 96 well plated in triplicate. One plate was frozen for storage, a second plate to be assayed for  $\beta$ -gal activity and the third

- 34 -

plate was *in vitro* differentiated as describe below into neuronal lineage to be assayed for  $\beta$ -gal activity.

In Vitro Differentiation of ES Cells into Neuronal Lineage

5

1. Split ES cells two days prior.
2. Change media on day prior.
3. Start differentiation. Trypsinize to single cells. Wash one with PBS.
- 10 4. Resuspend in 15-20 ml media  
7.5% FBS  
7.5% NBGS (lot tested)  
DMEM (no LIF)  
 $10^{-4}$  M bME
- 15 5. Plate  $1.5 \times 10^6$  cells per 10 cm bacterial grade petri dish.
6. Incubate at  $37^\circ\text{C}$  6%  $\text{CO}_2$  7 days to form embryoid bodies (EB).
7. Collect EB in 50 ml conical tube. Allow bodies to settle to bottom of tube and remove supernatant.
- 20 8. Wash EB in PBS (30ml).
9. Aspirate off PBS leaving 1 ml PBS. Add 3 ml Trypsin. Incubate for 5 minutes at  $37^\circ\text{C}$  taking care not to over trypsinize by monitoring trypsinization of EB under a microscope by transferring some EB to a 6 cm dish.
- 25 10. After trypsinization, pipette up and down to break up EB to single cell suspension. Trypsinize for an additional 1-2 minutes if there are still large clumps.
12. Count healthy cells.
- 30 13. Plate out densities of  $2 \times 10^5$  and  $4 \times 10^5$  on 3.5 cm dishes containing a mouse laminin (Becton Dickinson) coated coverslip. Final volume per dish is 2 ml. Avoid large clumps of cells by allowing them to settle out. Small clumps of 4-5 cells are desirable. Change media at 4-5 days. Analyze neuronal cells for  $\beta$ -gal activity after
- 35

- 35 -

7 days by staining with Xgal<sup>TM</sup> or by more sensitive techniques as described herein.

Example 2: Transcriptional Activation (Two hybrid system)

5

The two hybrid system is based on the fact that many eucaryotic transcriptional activators are comprised of two physically and functionally separable domains, a DNA-binding domain (DNA-BP) and an activation domain (AD).  
10 The two domains are normally part of the same protein. However, the two domains can be separated and expressed as distinct proteins. Two additional proteins (X and Y) are expressed as fusions to the DNA-BP and AD peptides. If X and Y interact, the AD is co-localized to the DNA-BP bound  
15 to the promoter, resulting in the transcription of the reporter gene.

The following is an example of the two hybrid transcriptional activation gene trap system. This system  
20 is composed of two fusion proteins, one component of which is expressed by a tissue- or cell- specific promoter and the second is found in a gene trap vector:

- 1) a fusion of protein X with the GAL4 DNA-BP;
- 25 2) a fusion of protein Y with the VP16 activation;

where protein X and Y interact (for example: the SV40 large T antigen which associates with the p53 protein). A  
30 third vector provides the GAL4 DNA binding site, the minimal promoter of the adenovirus Elb, and the lacZ reporter gene.

ES cells are first "seeded" with the third vector and  
35 a tissue-restricted promoter driving one component, for example: the CD11b promoter driving the expression of the

- 36 -

GAL4 DNA-BP fused to p53 peptide sequence. The vector may also contain a selectable marker such as PGK neo. The cells are then transfected with the second component found in a gene trap vector system. The gene trap vector may contain a gene encoding a fusion protein comprising the VP16 activation domain fused to the SV40 large T antigen preceded by a splice acceptor sequence and a IRES. The vector may also contain a selectable marker such as PGK-hygro. The ES cells are replica plated and some cells are allowed to differentiate and are then screened for  $\beta$ -gal activity.

Another example of this embodiment would be to use the following fusion proteins:

- 1) the GAL4 DNA binding domain fused to the Fos leucine zipper domain (DFosLZ), and
- 2) the VP16 activation domain fused to the Jun leucine zipper (AJunLZ); or
- 1) the GAL4 DNA binding domain fused to the Jun leucine zipper domain (DJunLZ), and
- 2) the VP16 activation domain fused to the Fos leucine zipper (AFosLZ).

The construction of these vectors have been previously described in Dang et al., (1991) Molecular and Cellular Biology, 11:954-962, and components to create the vectors of this system (except leucine zipper components) may be obtained from Clontech-Mammalian Matchmaker™ two hybrid assay kit.

An example of a reporter system whose expression is dependent on the presence of two interacting fusion

- 37 -

proteins is the G5E1bCAT vector which contains 5 copies of the 17 mer GAL4 DNA binding site 5' of the minimal promoter of the Adenovirus E1b driving the expression of the CAT reporter gene. The CAT reporter gene may also be replaced  
5 by the  $\beta$ -gal reporter gene or any other reporter gene. In order to adapt this to the complementation gene trap system, one component (for example DFosLZ) is driven by a tissue restricted promoter such as the CD11b promoter. The DFosLZ gene can be subcloned into a CD11b expression  
10 cassette (eg. as described in Dziennis, S. et al. (1995), Blood 85:319-329). The second component will be contained in a gene trap vector. The trap vector will be a variation of the IRES containing gene trap system described by Chowdhury et al., [supra] where the  $\beta$ geo gene is replaced  
15 with the AJunLZ gene.

Example 3: Transcriptional Activation  
(Genetic Recombination Dependent)

20 This system makes use of a vector containing a stuffer DNA fragment flanked by lox sites preceding a reporter gene similar to that described by Lasko, et al., (1992): Targeted Oncogene Activation by Site-Specific Recombination in Transgenic Mice; Proc. Natl. Acad. Sci. USA  
25 89:6232-6236. The expression of the reporter gene is dependent on the removal of the stuffer DNA sequence mediated by the Cre recombinase enzyme through site directed recombination of lox sites found flanking the stuffer DNA. The gene trap vector contains the Cre gene  
30 preceded by a splice acceptor sequence and an IRES. The gene trap vector may also contain a selectable marker.

Example 4: Selection/Screening System

35 In this embodiment, a selectable marker is driven by a tissue restricted promoter. For example, the myeloid



- 38 -

specific promoter CD11b may drive the expression of the puromycin resistance gene (puromycin n-acetyl transferase, *pac*). Such a vector may also contain PGK-hygro for ES cell selection. Cells would be transfected with a gene trap  
5 vector such as pGT4.5 which contains the lacZ reporter, and then allowed to differentiate and subsequently placed under selection with puromycin. Only myeloid specific cells survive the selection protocol. Those cells are then assayed for the expression of the reporter gene.

10

One factor that may influence the choice of embodiment of this invention is the ability of a chosen cell (eg. ES cells), to differentiate into a given cell type in vitro and the requirements of the specialized cells in order to  
15 grow and survive in the absence of other cell types (such as secondary stromal cells or feeder cells). If a specialized tissue or cell type is dependent on a second cell type for growth and survival, use of this section/screening embodiment may not be the ideal embodiment of this  
20 invention to use.

Since macrophage display endogenous  $\beta$ -gal activity which tends to mask complemented  $\beta$ -gal activity, and because macrophage cells can differentiate from hemopoietic  
25 stem cells in the absence of stromal cell interaction (when cytokines are added to suspension culture), the selection/screening system was carried out in a modification of the methods described in Example 1. This Example relies on expression of the entire lacZ gene and  
30 not alpha complementation of  $\beta$ -gal fragments. In order to differentiate between endogenous  $\beta$ -gal activity and the lacZ activity, a staining protocol at pH 8.5 that selectively detected lacZ activity and suppressed endogenous  $\beta$ -gal activity was employed. Also, use of the  
35 Galacto-star<sup>TM</sup> kit was shown to preferentially detect lacZ activity over endogenous mammalian  $\beta$ -gal.

### Vectors

A CD11b PURO vector was constructed as follows: a 660  
5 bp Sal I/HindIII fragment encoding the Puromycin acetyl  
transferase gene derived from pMXPURO construct was blunt  
ligated into the BamHI cloning site of the CD11b expression  
cassette containing the CD11b promoter and the human growth  
hormone minigene and polyadenylation signal, as described  
10 in Dzienni, S., et al. (1995) [*supra*]. A pGT4.5 gene trap  
vector containing the full length lacZ gene as described in  
Gossler, A. et al. (1989) [*supra*] was a gift from the  
laboratory of Dr. J. Rossant (Toronto, Ontario). A vector  
containing EMCV IRES flanked by BgIII sites was generated  
15 by digesting the pGT1.8IRES $\beta$ geo vector which was a gift of  
Dr. Austin Smith (described in Mountford, P. et al. (1994).  
Proc. Natl. Acad. Sci. U.S.A 91:4303-4307) with NcoI and  
ligating with self-overlapping oligomer 5' CATGGAGATCTC3'  
(SEQ. ID NO:5). The IRES sequence was then excised by  
20 digestion with pGT4.5 gene trap vector. A pGT4 IRES trap  
vector was constructed by ligating the BgII IRES fragment  
into the unique BgIII site in the pGT4.5 vector.

### ES Cell Culture

25

R<sub>1</sub> cells (Nagy et al. [*supra*]) were maintained in DMEM  
medium containing 15% FBS, 1000 U/ml LIF, 10<sup>-4</sup> M BMe, 2mM L-  
Glutamine, 1 mM Na Pyruvate, 50 IU Penicillin/ 50 $\mu$ g/ml  
Streptomycin, 0.1 mM non-essential amino acids (NEAA). To  
30 obtain stable lines between 5 x 10<sup>7</sup> and 1 x 10<sup>8</sup> cells were  
co-electroporated with 20 $\mu$ g CD11bPURO and 1 $\mu$ g PGK Hyg  
linearized plasmid DNA in a volume of 0.8 ml PBS using a  
BioRad Gene Pulser<sup>TM</sup> set at (240V 500 $\mu$ F). 5 x 10<sup>6</sup> cells  
were plated on gelatinized 10 cm tissue culture dishes and  
35 colonies were selected in 110 $\mu$ g/ml Hygromycin.  
Gelatinization of tissue culture dishes was accomplished by

- 40 -

coating the surface with 0.1% gelatin (SIGMA) for at least 10 minutes before aspiration of gelatin solution and allowing to air dry.

5     Selection of Clones that Express Puromycin in a Tissue Restricted Manner as Defined by the Chosen Promoter

Embryonic stem cells were co-electroporated with 20 $\mu$ g CD11b PURO vector linearized with HindIII and with 1 $\mu$ g PGKHyg linearized with HindIII plasmid DNA. Cells were  
10     cultured in ES cell medium containing LIF on gelatinized tissue culture dishes in the presence of 110 $\mu$ g/ml Hygromycin. After 9 days of culture, individual clones were picked and replica transferred into duplicate  
15     gelatinized 96-well tissue culture dishes to obtain one hygromycin resistant clone per well. Cells on one dish were stored by freezing. Cells on the second dish were caused to differentiate *in vitro*.

20     In Vitro Differentiation of CD11bPURO ES Cells into Hemopoietic Lineage

Iscove's differentiation medium was prepared as follows:

- 25     - Iscove's MDM medium  
       - 15% fetal bovine serum #603 - special batch tested serum for hemopoietic cell differentiation  
       - 2 mM glutamine  
30     - 450 uM monothioglycerol, MTG  
       - 40 ng/ml steel factor  
       - 10% 10x concentrated 3T3 conditioned medium  
       - 4% 10 x concentrated Wehi 3 conditioned medium

35     In vitro differentiation of CD11bpuro ES cells begin with the primary cultures, which after 8 days result in the formation of several large embryoid bodies. These embryoid

- 41 -

bodies were disrupted to obtain a single cell suspension which was subsequently cultured in the presence of puromycin for eight days. This secondary culture leads to the selection of hemopoietic cells, primarily macrophages.

5

### Primary Cultures

First, clones that were grown to 70% confluency on tissue culture treated 96 well plates were trypsinized by adding 20 $\mu$ l of Trypsin-EDTA to each well and incubated for 5 minutes at 37°C. Once the cells became detached, 60 $\mu$ l of Iscove's medium as described above with 5% serum was added to each well. Following vigorous mixing to break up clumps of cells and to obtain a single cell suspension, 20 $\mu$ l volumes from each clone were added to each of three low binding well Costar<sup>TM</sup> plates that already contained 180 $\mu$ l per well of differentiation medium. These plates were then incubated by 37°C and 6% CO<sub>2</sub> for eight days changing media when necessary. The remaining 20 $\mu$ l aliquots were transferred to a DMEM ES growth media-containing LIF in a 24 well plate and incubated to reach confluency and frozen.

### Secondary Cultures

25

Following eight days of incubation of the primary embryoid body cultures, the media was carefully removed using a multichannel pipettor. The embryoid bodies were washed three times with PBS. Subsequently, 100 $\mu$ l of Trypsin-EDTA was added to each well and the plates were incubated for 10 minutes at 37°C. The embryoid bodies were then disrupted by mixing 10 to 20 times with a multichannel pipettor and the single cell suspension was transferred to a round-bottom 96 well plate. These plates were centrifuges for 5 minutes at 1200 rpm and the cell pellets were resuspended in differentiation medium containing

- 42 -

puromycin at 0.2 $\mu$ g/ml and transferred to Costar<sup>TM</sup> low binding 96 well plates. The plates were then incubated for a further eight days at 37°C and 6% CO<sub>2</sub>, changing media when necessary. Cytospin analysis and staining of cells with  
5 May-Grunwald/Giemsa revealed that the majority of cells derived from the above culture conditions had a macrophage morphology. A CD11bPURO transfected ES cell clone (1D) was chosen due to its reproducibility in vitro to differentiate into a macrophage lineage upon culture with the above  
10 cytokine/growth factor cocktail and the presence of puromycin.

#### Electroporation of Gene Trap Vector

15 10 $\mu$ g of ScaI linearized pGT4IRES or pGT4.5 DNA was electroporated into the 1D ES cells, After 9 days of culture in the presence of 180 $\mu$ g/ml G418. 265 clones were picked and replica transferred into triplicate 96 well plates. One plate of cells was stored by freezing, another  
20 plate was stained with Xgal<sup>TM</sup> to analyze the expression of  $\beta$ -gal in the ES state and a third plate was differentiated in vitro into the hemopoietic lineage (as described above) and then stained with Xgal<sup>TM</sup>. One in 38 clones were positive in GT4IRES trapped ES clones, where one in 96  
25 clones were positive using the GT4.5 gene trap vector. One in 200 clones were positive in macrophage cells using the GT4IRES vector. Staining for  $\beta$ -gal activity in macrophage was done at pH8.5 in order to suppress endogenous  $\beta$ -gal activity and selectively detect the gene trap vector  
30 derived lacZ activity. No background activity was detected at pH 8.5, thus the presence of stain was a positive event.

#### Example 5: Co-expression of Two Reporter Genes

35 An example of this embodiment is where ES cells are first seeded with one reporter (such as the human CD8 cell

- 43 -

surface protein) driven by a myeloid specific promoter, such as CD11b. The vector may also contain a selectable marker such as PGK hygromycin for ES cell clone selection. The cells are then transfected with a gene trap vector comprising, for example, the green fluorescent protein preceded by a splice acceptor sequence and followed by an IRES sequence. The gene trap vector may also contain a selectable marker such as PGK neo. Individual clones are replica plated and some cells are allowed to undergo differentiation and are subsequently screened for dual expression of the reporter genes by immunofluorescence and FACS analysis. The cells are stained with a monoclonal antibody directed against the human CD8 cell surface protein that is conjugated to phyco-erythrin. Cells are then subsequently analysed for red and green fluorescence by FACS.

#### Example 6: Luciferase - GFP Pathway

A pathway system that may be utilized is a luciferase and green fluorescent protein (GFP) system derived from bioluminescent coelenterates such as the jellyfish *Aequorea victoria* or the sea pansy *Renilla reniformis*. The GFP serves as an energy-transfer acceptor, receiving energy from a  $\text{Ca}^{2+}$ -activated photoprotein or a luciferase-oxyluciferin complex in *A. victoria* and *R. reniformis*, respectively. Aequorin is a 21 kDa apoprotein which is complexed with molecular oxygen and coelenterazine. When aequorin is activated by  $\text{Ca}^{2+}$ , it catalyzes the oxidation of the coelenterazine to coelenteramide, which is in an activated state. Coelenteramide returns to its ground state, emitting blue light at 470 nm. Energy transfer to GFP occurs from the excited state of coelenteramide complex with aequorin. GFP absorbs 470 nm light energy from activated aequorin and emits green light at 510 nm.

- 44 -

The following procedure demonstrates this pathway system in human embryonal kidney cells. pQB125 (Quantum Biotechnologies Inc.) is a vector containing the red shifted mutant coding sequences of green fluorescent protein (GFP) driven by the CMV promoter. A pCMV-Aequorin vector was prepared according to Brini, et al. (1995) J. Biol. Chem. 270:9896-9903. Transient transfection by "superfection (QIAGEN) was performed according to the manufacturer's instructions. Human 293 embryonal kidney cells were transfected with pQB125 alone, pCMV-Aequorin vector alone or with pQB125 and pCMV-Aequorin. After 24-48 hours post transfection, cells were incubated with a solution containing PBS and 125  $\mu$ M Coelenterazine (Molecular Probes, Oregon) for 30 minutes. Cells were then washed once with PBS and lysed with 0.1% Triton X-100<sup>TM</sup> and 50 mM CaCl<sub>2</sub> solution. Luminescence was measured in a MLX<sup>TM</sup> Microtitre plate luminometer (DYNEX). Samples were performed in duplicate and read with and without a longwave bandpass filter (500 nm cutoff; Chromatech) added to the luminometer detector to block out transmission of wavelengths below 500 nm. The results are set out below.

Plasmids Transfected	Relative Light Units (RLU) Without Filter (0-600nm)	Relative Light Units With Filter	Percent Transmission
pCMVAequorin	114 632	18 296	16%
pQB125	1 131	215	19%
PCMVAequorin+pQB125	121 937	59 266	49%

This example may be adapted for use in this invention by preparation of DNA constructs similar to those shown in the Figures. A trap vector is prepared by placing either the Aequorin or the GFP coding sequence downstream of a splice acceptor with an optional IRES upstream of the coding sequence. A vector containing the desired promoter having restricted expression is prepared in which the

- 45 -

promoter drives either the Aequorin or the GFP coding sequences.

5 All publications and patents cited in this specification are incorporated herein by reference. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of skill in the art in light of the prior art and the  
10 teachings of this specification that various changes and modification may be made to the invention described without departing from the spirit or scope of the appended claims.



- 46 -

WE CLAIM:

1. A method of detecting a target gene having restricted expression in a eucaryotic organism, which comprises the steps of:
- 5 (i) transforming a eucaryotic cell with a DNA sequence encoding a first indicator component under the control of a promoter having restricted expression;
- 10 (ii) transforming the cell of (i) or a descendent of the cell by operably integrating into the cell's genome, DNA lacking a promoter but which comprises a sequence encoding a second indicator component;
- 15 (iii) producing tissue or specialized cells from the cell of (ii); and
- (iv) monitoring the tissue or specialized cells of (iii) for a detectable indicator resulting from both the first and second indicator components.
2. The method claim 1 wherein the eucaryotic cell is an ES cell.
- 20
3. The method of claims 1 and 2 wherein the first and second indicator components are inactive fragments or subunits of an enzyme which, when combined, provide an active enzyme detectable by its activity.
- 25
4. The method of claim 1 or 2 wherein the first and second indicator components are independently detectable or selectable, and the detectable indicator is the presence of both indicator components in a cell.
- 30
5. The method of claim 1 or 2 wherein the first and second indicator components react in a sequence of reactions which result in a detectable indicator.
- 35

- 47 -

6. The method of any one of claims 1-5 which comprises the additional step of isolating DNA endogenous to the eucaryotic cell which flanks integrated DNA comprising the second indicator component.

5

7. A method of producing an eucaryotic organism comprising a detectable indicator associated with a target gene having restricted expression, comprising steps (i) and (ii) of claim 1 to produce a transformed cell, followed by the step of growing an eucaryotic organism from said transformed cell.

10

8. The method of claim 7 wherein the eucaryotic organism is a non-human mammal and the transformed cell is an ES cell.

15

9. A DNA construct comprising, in a 5' to 3' direction, a splice acceptor and a sequence encoding an inactive subunit or fragment of an enzyme, wherein said subunit or fragment is active when combined with a further subunit or fragment of an enzyme.

20

10. The DNA construct of claim 9 wherein the sequence encodes an alpha or omega fragment of  $\beta$ -galactosidase.

25

11. The DNA construct of claim 9 or 10 further comprising an IRES.

12. The combination of:

30

(i) a DNA construct for integration into the genome of an eucaryotic cell comprising a sequence encoding a first indicator component under the control of a promoter having restricted expression; and

(ii) A DNA construct for integration into the genome of a eucaryotic cell, comprising in the 5' to 3' direction, a splice acceptor and a sequence encoding a second

35

- 48 -

indicator component and an optional IRES,  
wherein expression of both the first and second indicator  
components in said cell is detectable.

- 5 13. A eucaryotic cells transformed by the combination of  
DNA constructs of claim 12.

14. The cell of claim 13 which is an ES cell.

1/1




FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 4

Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (12-97)  
Approved for use through 9/30/00. OMB 0651-0032

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)</b>	Attorney Docket Number	80135
	First Named Inventor	Christopher J. Ong
	<i>COMPLETE IF KNOWN</i>	
	Application Number	/
	Filing Date	
	Group Art Unit	
<input type="checkbox"/> Declaration Submitted with Initial Filing	OR	<input type="checkbox"/> Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required)
Examiner Name		

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

COMPLEMENTATION TRAP

the specification of which

(Title of the Invention)

☐ is attached hereto  
OR

☒ was filed on (MM/DD/YYYY) July 10, 1998 as United States Application Number or PCT International

Application Number PCT/CA98/00677 and was amended on (MM/DD/YYYY) (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
2,205,888	Canada	7/11/97	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/01 (12-97)  
Approved for use through 9/30/00. OMB 0651-0032  
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## DECLARATION — Utility or Design Patent Application

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)
PCT/CA98/00677	7/10/98	

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

☐ Customer Number

OR

☒ Registered practitioner(s) name/registration number listed below

Place Customer  
Number Bar Code  
Label here

Name	Registration Number	Name	Registration Number
Eugenia Garrett-Wackowski	37,330		

☐ Additional registered practitioner(s) named on supplemental Registered Practitioner Information sheet PTO/SB/02C attached hereto.

Direct all correspondence to: ☐ Customer Number  or Bar Code Label

OR ☒ Correspondence address below

Name	Eugenia Garrett-Wackowski				
Address	Townsend and Townsend and Crew LLP				
Address	Two Embarcadero Center, 8th Fl.				
City	San Francisco	State	CA	ZIP	94111
Country	US	Telephone	415-576-0200	Fax	415-576-0300

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor:		<input type="checkbox"/> A petition has been filed for this unsigned inventor					
Given Name (first and middle (if any))			Family Name or Surname				
Christopher J.			Ong				
Inventor's Signature					Date		
Residence: City	Vancouver	State	B.C.	Country	Canada	Citizenship	CA
Post Office Address	101-688 West 12th Avenue						
Post Office Address							
City	Vancouver	State	B.C.	ZIP	V5Z 1M8	Country	Canada

☒ Additional inventors are being named on the 1 supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto

Please type a plus sign (+) inside this box → ☐

PTO/SB/02A (3-97)  
Approved for use through 9/30/98. OMB 0651-0032  
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## DECLARATION

ADDITIONAL INVENTOR(S)  
Supplemental Sheet  
Page 1 of 1

Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name (first and middle [if any])				Family Name or Surname			
John J.				Priatel			
Inventor's Signature				Date			
Residence: City		West Vancouver		State		B.C.	
				Country		Canada	
Post Office Address		5407 Westhaven Place					
Post Office Address							
City		West Vancouver		State		B.C.	
				ZIP		V7W 3G1	
				Country		Canada	
Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name (first and middle [if any])				Family Name or Surname			
Frank R.				Jirik			
Inventor's Signature				Date			
Residence: City		Vancouver		State		B.C.	
				Country		Canada	
Post Office Address		103-146 West 13th Avenue					
Post Office Address							
City		Vancouver		State		B.C.	
				ZIP			
				Country		Canada	
Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name (first and middle [if any])				Family Name or Surname			
Inventor's Signature				Date			
Residence: City				State			
				Country			
Post Office Address							
Post Office Address							
City				State			
				ZIP			
				Country			

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.